Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is Accendra Health (ACH) Stock Down -35.08% Today?

Why Is Accendra Health (ACH) Stock Down -35.08% Today?

Key Takeaways

  • Accendra Health shares plunged 35.08%, or $0.0463, to close at $0.0857 — a record low — down from the prior close of $0.1320.
  • The primary catalyst was the New York Stock Exchange's decision to commence delisting proceedings against the common stock under Section 802.01D for "abnormally low selling price," with trading suspended immediately.
  • Secondary pressure came from options exchanges moving to delist ACH contracts effective Nov. 17, and from the fact that a proposed reverse split no longer cures the listing problem.
  • The collapse was company-specific: a third-quarter earnings miss, slashed guidance and shrinking cash have left the equity trading as a distressed micro-cap.
  • News Significance Score: 75/100 - Exchange delisting notice is a terminal listing event; the 35% slide was about five times the stock's typical daily move.
  • Traders are now watching a possible appeal to the NYSE board committee, OTC trading arrangements, the December reverse-split vote and fourth-quarter results due Feb. 24, 2027.
  • For deeper research, readers can review Price Targets, Earnings and Forecast pages dedicated to the stock.
  • Investors who want to see which strategies are working in the current tape can explore Trending AI Robots.

Accendra Health Stock Hits a Record Low

Accendra Health, Inc. (ACH) is a Glen Allen, Virginia-based provider of home-based care products and services through the Apria and Byram Healthcare brands; it was formerly known as Owens & Minor and began trading under its new name and symbol in January 2026. The stock closed Monday at $0.0857, down $0.0463, or 35.08%, from Friday's close of $0.1320 — a decisive move downward to an all-time low. The immediate reason cited by the market was the exchange's move to begin delisting the shares, a step the company had been fighting since early October.

NYSE Delisting Proceedings: The Primary Catalyst

NYSE Regulation determined that the common stock is no longer suitable for listing because of "abnormally low selling price" levels under Section 802.01D of the Listed Company Manual and said trading would be suspended immediately. The exchange will apply to the Securities and Exchange Commission to delist the stock once all procedures, including any company appeal to a committee of the NYSE board, are complete. The action supersedes earlier cures: the company received a notice on Oct. 6 for trading below $1.00 over 30 sessions and a second notice in late October for failing minimum market capitalization and equity thresholds, then submitted a compliance plan built largely around a reverse stock split slated for a December shareholder vote. That remedy is now overtaken by the delisting decision.

The Underlying Distress Behind the Selling

The listing failure is a symptom, not the disease. Third-quarter results published Nov. 5 showed an adjusted loss of $0.23 per share against expectations near break-even and revenue of $601.8 million, down 14% year over year and below consensus. Adjusted EBITDA roughly halved to $47.8 million as payer audits delayed collections and squeezed roughly $10 million of revenue and profit out of the quarter. Management cut full-year 2026 revenue guidance to $2.45 billion–$2.55 billion and adjusted EBITDA to $300 million–$320 million, while cash fell to $26.6 million from $282.0 million at the start of the year. Against roughly $1.8 billion of debt and negative shareholders' equity, the equity's residual value is what the price now debates.

Options markets added to the pressure: exchange notices confirmed ACH options will be delisted from several options exchanges effective Nov. 17, removing a hedging and speculation outlet precisely when holders wanted one.

Market Context and Trading Activity

Volume of about 3.2 million shares was roughly 1.2 times the 50-day average near 2.6 million — elevated, but restrained for a listing event, consistent with a thin order book in a sub-$0.10 name. The stock set an intraday low of $0.0817, broke decisively below every recent support level, and now trades about 98% below its 52-week high of $4.69. The move was idiosyncratic rather than sector-driven; home-care and medical-distribution peers did not mirror a decline of this scale, and the selloff reflects the specific loss of exchange listing and access to public capital. A post-close announcement that Blue Shield of California expanded its collaboration with Apria and Byram was far too small to offset the listing news.

News Significance Score

The score runs from 0 — no meaningful news and a move that is normal for the stock — to 100, meaning transformative news and an extreme, rare price move. Here the score is 75 out of 100. The verified news is materially significant: an exchange commencing delisting proceedings is close to a terminal event for a micro-cap equity and directly threatens liquidity and index eligibility. The price move was also far outside normal: the 35.08% decline was roughly five times the stock's average absolute daily move of about 6.9% over the last 60 sessions, and no session in that window produced a larger one-day drop, though a 31.87% slide on Nov. 6 came close. Strong news plus an unusually large move combine into the score.

What Comes Next for ACH

The company can request a review by a committee of the NYSE board, and the timing and outcome of that process are the nearest swing factors; absent a successful appeal, trading would migrate to the over-the-counter market, where spreads widen and institutional participation typically disappears. The planned reverse split still faces a December shareholder vote, but even approval would not automatically restore the listing. Operationally, investors will focus on fourth-quarter results expected Feb. 24, 2027, cash burn and liquidity, the pace of payer-audit collection delays, and whether asset sales or further liability management can stabilize a leveraged balance sheet. A leadership transition — with a new chief executive installed and the chief operating officer stepping into an advisory role — adds execution risk to an already narrow path.

Trending AI Robots

Tickeron's Trending AI Robots page curates the bots that are performing best in current market conditions from a library of hundreds of AI trading bots covering thousands of tickers. Because bots differ widely by strategy, timeframe, performance metrics and traded symbols, the trending list offers a practical starting point for comparing approaches side by side. Readers looking for ideas beyond a single distressed name may find it a useful next stop.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ACH

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ACH in +11.25% Uptrend, growing for three consecutive days on November 03, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ACH advanced for three days, in 220 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACH as a result. In 78 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for ACH entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.028) is normal, around the industry mean (14.423). P/E Ratio (-0.051) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (2.016). Dividend Yield (0.013) settles around the average of (0.134) among similar stocks. P/S Ratio (0.031) is also within normal values, averaging (4.260).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ACH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.

Notable companies

The most notable companies in this group are McKesson Corp (NYSE:MCK).

Industry description

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

Market Cap

The average market capitalization across the Medical Distributors Industry is 23.75B. The market cap for tickers in the group ranges from 44.8K to 123.68B. MCK holds the highest valuation in this group at 123.68B. The lowest valued company is COCM at 44.8K.

High and low price notable news

The average weekly price growth across all stocks in the Medical Distributors Industry was -13%. For the same Industry, the average monthly price growth was -25%, and the average quarterly price growth was -28%. MCK experienced the highest price growth at 0%, while ACH experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Medical Distributors Industry was 60%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 48
Price Growth Rating: 61
SMR Rating: 88
Profit Risk Rating: 73
Seasonality Score: -2 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of alumina, primary aluminum and aluminum fabricated products

Industry MedicalDistributors

Industry
Aluminum
Address
10900 Nuckols Road
Phone
+1 804 277-4304
Employees
6500
Web
https://www.accendrahealth.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.